No more Covid jabs, millions are told - as experts hit out at 'reckless decision' to block all but one age group from further boosters
Invites won't be dished out to up to six million pensioners aged 65-74, who were eligible during the pandemic.
Only those over the age of 75, those living in care homes and others who are immunosuppressed will be able to come forwards for a jab.
Experts labelled the move a 'hugely concerning' and 'reckless decision' warning cases could shoot up before the vulnerable get their top-up jab.
Scientists were alarmed last month after a new Covid variant dubbed 'Stratus' and believed to to be more infectious than previous Covid strains, soared to dominance in the UK.
But the Joint Committee on Vaccination and Immunisation (JCVI), which guides ministers on jab rollouts, argued that additional Covid doses provide 'very limited, if any, protection against infection' given the 'high population immunity' to the virus.
Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association, said the JCVI's decision was a 'hugely concerning, a reckless decision'.
She added: 'By restricting access to jabs this autumn ahead of peak Covid season, there is a serious risk that Covid cases in this age group increase compared to previous years putting even greater pressure on the NHS.
'Saving a few pounds by not giving a patient a jab could end now up leaving the NHS with a bill for thousands, if that patient ends up hospitalised with Covid later on.
'Many patients will feel they need to pay privately to get protection.
'We urge the JCVI and the government to think again and make everyone 65 and over in England eligible for an NHS COVID jab from their local pharmacy.'
She also said it was 'madness' for the UK to restrict jabs, when other nations including Germany and the United States were still recommending the vaccines for all pensioners.
'To deny millions of seniors their COVID jab this year is to take an unacceptable risk with patient health and risks producing a winter crisis the NHS simply won't be able to cope with,' Dr Hannbeck added.
A Department of Health and Social Care (DHSC) spokesperson said: 'This decision is based on expert advice from the JCVI, which continuously monitor and evaluate emerging scientific evidence on Covid vaccines.
'The autumn 2025 vaccination programme will target people who are at the highest risk of serious illness to protect the most vulnerable. We encourage anyone who is eligible for Covid vaccination to come forward for vaccination this autumn.'
Under the JCVI's advice, frontline NHS workers and care staff will also no longer be offered free jabs.
'In the current era of high population immunity to Covid, additional Covid doses provide very limited, if any, protection against infection and any subsequent onward transmission of infection,' they said.
The vaccines are estimated to have saved tens of millions of lives globally from Covid, 1.6million in Europe and 3million in the US.
They are also credited with helping end the series of paralyzing lockdowns brought on by the Covid pandemic.
In the UK, ministers have repeatedly said they won't resort to imposing lockdowns unless a doomsday Covid variant appears.
A wall of immunity among the population—built up by repeated waves of infection and vaccine rollouts—has given officials confidence to consign pandemic-era measures to history.
Spikes in Covid cases can still cause mass illness across the country, sparking chaos in schools, the health service and public transport.
But officials also no longer track the prevalence of the virus in the same way they used to, as part of the Government's ushering in of pre-Covid normalities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech
Aug 7 (Reuters) - German drugmaker CureVac ( opens new tab and GSK (GSK.L), opens new tab reached an agreement with BioNTech ( opens new tab and Pfizer (PFE.N), opens new tab on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S. The settlement comes after BioNTech agreed to acquire its domestic peer CureVac in a $1.25 billion all-stock deal in June. Three years ago, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the company and two of its subsidiaries for infringement of its intellectual property rights. CureVac had said that its claim to intellectual property rights was based on more than two decades of work on mRNA technology, some of which was used by BioNTech and Pfizer for the development and sale of their Comirnaty coronavirus vaccine. CureVac's efforts to develop an mRNA-based COVID-19 vaccine did not come to fruition during the pandemic, whereas BioNTech and its partner Pfizer chalked up more than $40 billion in combined vaccine sales in 2021 and 2022.
The Independent
3 hours ago
- The Independent
Near 50% rise in people contacting NSPCC over children's welfare in sports settings, charity says
The number of people contacting a helpline with concerns about the welfare of young people in sports clubs rose by almost 50 per cent in a year, a children 's charity has said. The NSPCC said the rise might have been prompted by greater awareness following high-profile investigations into sports settings in recent years, as well as increased knowledge about the helpline. It said said the jump also 'possibly shows a rise in the abuse of children in sports settings', but noted that adult survivors have also been reporting historic abuse to the helpline. The NSPCC Helpline had 623 contacts from adults across the UK with concerns about a child's welfare in a sports setting in the 12 months to the end of March. This was up from 425 the previous year – a rise of 47 per cent. The most common concerns raised by contacts to the helpline were about sexual abuse or exploitation, emotional abuse and physical abuse. Christian McMullan, NSPCC professional learning services director, said it is 'vital that parents, carers, staff and volunteers not only know how to spot the signs that a child may be experiencing difficulties, but also what to do and who to speak to, so that a child can be supported'. He added: 'Our Keeping Your Child Safe in Sport resources are free, easy to access and use, and can help adults understand more about what role they can play in ensuring young people can enjoy their sport in safety.'
The Independent
3 hours ago
- The Independent
Cancer patients to receive ‘game-changing' vaccine in new NHS trial
Patients in England with head and neck cancer will be fast-tracked onto a clinical trial for a "potentially transformative" new vaccine, under an initiative announced by the NHS. The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancerous cells, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50 per cent. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK -funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer, you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'
